Chapter 9 GM2 gangliosidoses

Amos D. Korczyn*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

LOGM2G results from the defective activity of the lyosomal enzyme β-hexosaminidase A. Continued accumulation of undegraded substrate results in pathology in the central nervous system. The disease is progressive and disease dynamics may vary throughout life. Clinically, the disease variants present a remarkable spectrum of phenotypes ranging from the lethal form to a slowly progressive disease type. Genotype/phenotype correlations are imperfect. Homozygosity for the L444P genotype is almost always associated with the infantile form. The pathological mechanism of the central nervous system damage is still not fully understood. Neuronal loss and neurodegeneration have been reported, as well as gray matter and white matter involvement, leading to multisystem expression. Recently, the possibilities of using stem cells to replace damaged neurons or enzyme replacement therapy have been suggested for several neurodegenerative diseases. The anterior horn cells can theoretically be a target for this procedure. In fact, using stem cells engineered to carry a normal HEXA gene is potentially more likely to benefit LOGM2G cases than patients with other forms of motor neuron disease, since in ALS the degenerative process will continue and is likely to affect the transplanted cells whereas in LOGM2G a real correction of the metabolic abnormality could replace damaged motor neurons by normal ones.

Original languageEnglish
Title of host publicationMotor neuron disorders and related diseases
EditorsAndrew Eisen, Pamela Shaw
Pages171-177
Number of pages7
DOIs
StatePublished - 2007

Publication series

NameHandbook of Clinical Neurology
Volume82
ISSN (Print)0072-9752

Fingerprint

Dive into the research topics of 'Chapter 9 GM2 gangliosidoses'. Together they form a unique fingerprint.

Cite this